InterGenetics

InterGenetics was a biotechnology company dedicated to the development of genetic-based diagnostic tools for cancer risk assessment. The company's flagship product, OncoVue, represented one of the first commercially available polygenic risk tests for breast cancer. This test analyzed a patient's DNA for specific single nucleotide polymorphisms (SNPs) associated with breast cancer susceptibility, combining this data with personal medical history. Headquartered in Oklahoma City, the firm aimed to bridge the gap between genomic research and clinical practice through personalized risk stratification. Despite early clinical interest and partnerships, the company faced challenges in the evolving molecular diagnostics market and is no longer active.